
Partners to target autoimmune Fc receptors using nanobodies
Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases. The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that… Read More
